Cancer Statistics, 2021.
Reads0
Chats0
TLDR
In the United States, the cancer death rate has dropped continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment as mentioned in this paper.Abstract:
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.read more
Citations
More filters
Journal ArticleDOI
Interaction between DNMT3B and MYH11 via hypermethylation regulates gastric cancer progression.
TL;DR: In this article, the expression of myosin heavy chain 11 (myH11) in GC and mechanisms related were examined via the SangerBox platform and the relationship between MYH11 expression and patients' prognosis was analyzed.
Journal ArticleDOI
Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis.
Marko Damm,Ljupcho Efremov,Benedikt Birnbach,Gretel Terrero,Jörg Kleeff,Rafael T. Mikolajczyk,Jonas Rosendahl,Patrick Michl,Sebastian Krug +8 more
TL;DR: In this paper, the authors evaluated the impact of first-line neoadjuvant therapy with GNP in patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC).
Journal ArticleDOI
Desorption Electrospray Ionization Mass Spectrometry Assay for Label‐Free Characterization of SULT2B1b Enzyme Kinetics
TL;DR: A novel label‐free assay based on high‐throughput (>1 Hz) desorption electrospray ionization mass spectrometry (DESI‐MS) for the direct quantitation of the sulfoconjugated product that is particularly promising for identification of SULT2B1b inhibitors with potential as prostate cancer therapeutics.
Journal ArticleDOI
Obesity and Pancreatic Cancer: Insight into Mechanisms.
Guido Eibl,Enrique Rozengurt +1 more
TL;DR: A recent review as discussed by the authors discusses selected topics and mechanisms that attracted recent interest and that may underlie the promoting effects of obesity in pancreatic cancer, including the impact of obesity on KRAS activity, the role of visceral adipose tissue, intrapancreatic fat, adiposes tissue inflammation, and adipokines, and current research on lipocalin-2, fibroblast growth factor 21, and Wnt5a is discussed.
Journal ArticleDOI
Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation
Zheng Wang,Anqi Sun,Aihui Yan,Jian-Er Yao,Haibo Huang,Zi-Ming Gao,Tao Han,Jia Gu,Ni Li,Huizhe Wu,Kai Li +10 more
TL;DR: In this article , the microtubule cross-linking factor 1 circRNA (circMTCL1, circ0000825) exerts its critical oncogenic functions by promoting complement C1q-binding protein (C1QBP)-dependent ubiquitin degradation and subsequently activating Wnt/β-catenin signalling in laryngeal squamous cell carcinoma initiation and development.
References
More filters
Journal ArticleDOI
Cancer statistics, 2019.
TL;DR: The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Journal ArticleDOI
Cancer statistics, 2016
TL;DR: Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
Journal ArticleDOI
Sex differences in immune responses
Sabra L. Klein,Katie L. Flanagan +1 more
TL;DR: It is emphasized that sex is a biological variable that should be considered in immunological studies and contribute to variations in the incidence of autoimmune diseases and malignancies, susceptibility to infectious diseases and responses to vaccines in males and females.
Journal ArticleDOI
Colorectal cancer statistics, 2020.
Rebecca L. Siegel,Kimberly D. Miller,Ann Goding Sauer,Stacey A. Fedewa,Lynn F. Butterly,Lynn F. Butterly,Joseph C. Anderson,Joseph C. Anderson,Andrea Cercek,Robert A. Smith,Ahmedin Jemal +10 more
TL;DR: Progress against CRC can be accelerated by increasing access to guideline‐recommended screening and high‐quality treatment, particularly among Alaska Natives, and elucidating causes for rising incidence in young and middle‐aged adults.